KGC
ABBV icon

Kennon-Green & Company’s AbbVie ABBV Stock Holding History

Kennon-Green & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$343K Sell
1,311
-40
-3% -$10.3K 0.26% 37
2026
Q2 		$340K Sell
1,351
-10
-0.7% -$2.15K 0.27% 38
2026
Q1 		$296K Sell
1,361
-25
-2% -$5.55K 0.24% 37
2025
Q4 		$317K Sell
1,386
-71
-5% -$16.2K 0.25% 36
2025
Q3 		$337K Sell
1,457
-3
-0.2% -$611 0.26% 37
2025
Q2 		$277K Buy
1,460
+15
+1% +$2.79K 0.22% 38
2025
Q1 		$303K Sell
1,445
-25
-2% -$4.86K 0.25% 39
2024
Q4 		$261K Sell
1,470
-30
-2% -$5.52K 0.23% 41
2024
Q3 		$296K Sell
1,500
-4
-0.3% -$747 0.25% 40
2024
Q2 		$258K Sell
1,504
-77
-5% -$12.8K 0.24% 40
2024
Q1 		$288K Sell
1,581
-25
-2% -$4.31K 0.27% 40
2023
Q4 		$249K Sell
1,606
-105
-6% -$15.3K 0.25% 40
2023
Q3 		$255K Sell
1,711
-46
-3% -$6.75K 0.25% 43
2023
Q2 		$237K Sell
1,757
-25
-1% -$3.67K 0.22% 43
2023
Q1 		$284K Sell
1,782
-75
-4% -$11.5K 0.27% 40
2022
Q4 		$300K Buy
+1,857
New +$285K 0.3% 37

Other funds holding ABBV

FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Violich Capital Management San Francisco, California $927M AUM 28.93% 1-Year Est. Return
PNC
Park National Corp Newark, Ohio $3.69B AUM 18.32% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.48B AUM 34.49% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.07B AUM 21.73% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
PWM
Pacific Wealth Management San Diego, California $227M AUM 24.81% 1-Year Est. Return
TF
Tompkins Financial Ithaca, New York $1.42B AUM 19.14% 1-Year Est. Return

Kennon-Green & Company's ABBV Position: Q3 2026 in Review

Kennon-Green & Company reduced its AbbVie (ABBV) stake by 3% in Q3 2026, selling an estimated $10.3K and leaving 1,311 shares worth $343K. The position accounts for 0.26% of the portfolio, ranked #37.

Kennon-Green & Company first reported a position in ABBV in Q4 2022 and has held it in 16 quarters since. 49 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Kennon-Green & Company held 1,311 shares of AbbVie worth $343K as of Q3 2026.
  • Kennon-Green & Company sold 40 AbbVie shares in Q3 2026, an estimated $10.3K.
  • AbbVie made up 0.26% of Kennon-Green & Company's portfolio in Q3 2026, its #37 holding.
  • Kennon-Green & Company first reported a position in AbbVie in Q4 2022 and has held it in 16 quarters since.
  • 49 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Kennon-Green & Company's 13F filing for Q3 2026, filed 5 Oct 2026.